SCD is a devastating inherited hemolytic disorder that affects red blood cells (RBCs) and is caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position of the β-globin chain of hemoglobin [1] [2] [3] . Despite our precise knowledge of the molecular defect that is associated with sickle hemoglobin (HbS) in RBCs 1,4 and recent progress in understanding the molecular events that control polymerization of HbS and sickling of erythrocytes [5] [6] [7] [8] [9] , the specific factors and signaling pathways that are involved in this process are unclear. As a result, we lack effective preventative approaches or mechanism-specific treatment options for the disease. Thus, defining the molecular mechanisms underlying erythrocyte sickling is essential for advancing our understanding of the pathogenesis of SCD and for developing new treatment strategies.
SCD is a devastating inherited hemolytic disorder that affects red blood cells (RBCs) and is caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position of the β-globin chain of hemoglobin [1] [2] [3] . Despite our precise knowledge of the molecular defect that is associated with sickle hemoglobin (HbS) in RBCs 1, 4 and recent progress in understanding the molecular events that control polymerization of HbS and sickling of erythrocytes [5] [6] [7] [8] [9] , the specific factors and signaling pathways that are involved in this process are unclear. As a result, we lack effective preventative approaches or mechanism-specific treatment options for the disease. Thus, defining the molecular mechanisms underlying erythrocyte sickling is essential for advancing our understanding of the pathogenesis of SCD and for developing new treatment strategies.
Hypoxic conditions are known to promote deoxygenation and subsequent polymerization of HbS, resulting in RBC sickling, hemolysis and eventual end organ damage 10, 11 . Many factors and metabolites are altered in response to hypoxia and may contribute to the pathogenesis of the disease. In an effort to identify metabolites that contribute to sickling and thereby exacerbate disease pathogenesis, we used liquid and gas chromatography coupled with mass spectral analysis to measure and compare metabolite profiles in the whole blood of control mice and SCD transgenic mice, an accepted animal model of SCD 12, 13 .
RESULTS
Excess adenosine contributes to mouse erythrocyte sickling Metabolomic profiling revealed that adenosine was among the metabolites most highly elevated in the whole blood of SCD transgenic mice compared to controls (Supplementary Fig. 1 ). Adenosine concentration was also significantly elevated in the plasma of SCD transgenic mice (P < 0.05; Fig. 1a,b) . The concentration of adenosine, a signaling nucleoside, increases under hypoxic conditions owing to the degradation of extracellular ATP derived from affected cells or tissues 14 . Hypoxia is the initial trigger that induces erythrocyte sickling, but it is unknown whether increased adenosine is involved in this process.
To determine whether increased adenosine levels contribute to SCD in vivo, we treated SCD transgenic mice with polyethylene glycolmodified adenosine deaminase (PEG-ADA), a drug that has been successfully used for more than 20 years to lower adenosine concentrations in ADA-deficient humans 15, 16 (Fig. 1b) . PEG-ADA treatment is well tolerated by ADA-deficient humans and mice 15, 17 and produced no obvious adverse side effects in SCD transgenic mice (data not shown). After 8 weeks of PEG-ADA treatment, blood smear analysis and reticulocyte flow cytometry showed that the percentages of sickled RBCs and reticulocytes were significantly reduced (P < 0.05; Fig. 1c and Table 1 ). This finding provides evidence that increased adenosine levels contribute to chronic sickling in SCD transgenic mice.
Erythrocyte sickling is the primary cause of intravascular hemolysis. Because PEG-ADA enzyme therapy reduced sickling in SCD transgenic mice, we tested whether chronic treatment with PEG-ADA would ameliorate hemolysis. We treated SCD transgenic mice with PEG-ADA for 8 weeks to lower adenosine concentrations and reduce erythrocyte sickling as described above. Intravascular hemolysis in these mice was significantly reduced by PEG-ADA treatment as a r t i c l e s 8 0 VOLUME 17 | NUMBER 1 | JANUARY 2011 nature medicine demonstrated by decreased plasma hemoglobin concentration, increased plasma haptoglobin concentration and decreased total bilirubin concentration (P < 0.05; Fig. 1d-f) . We also found that the half-life of RBCs in SCD transgenic mice increased from 2 d to 4 d after chronic PEG-ADA treatment (Fig. 1g) . Complete blood count analysis showed that chronic PEG-ADA treatment significantly increased the total number of RBCs, hemoglobin concentration and hematocrit and lowered the total number of white blood cells (WBCs; P < 0.05; Table 1 ). The increase in hematocrit ( Table 1) presumably reflects the corresponding increase in RBC numbers. Red cell distribution width (RDW) was also significantly reduced by PEG-ADA treatment (P < 0.05; Table 1 ), suggesting that the sizes of RBCs were more uniform and regular in treated than untreated mice. These results show that decreased sickling, reduced hemolysis and prolonged lifespan of RBCs in SCD transgenic mice treated with PEG-ADA resulted in significantly increased erythrocyte number and total hemoglobin content and decreased inflammatory response.
Elevated adenosine leads to multi-tissue damage in mice In addition to hemolysis, sickling also led to tissue damage in SCD transgenic mice. Histological analysis showed that vascular congestion, vascular damage and necrosis in lung, liver and spleen of SCD transgenic mice were improved by chronic treatment with PEG-ADA (Fig. 2a) . The ratio of spleen weight to body weight was significantly reduced, from 4.52 ± 0.24 to 2.48 ± 0.36, after chronic PEG-ADA treatment (P < 0.05, n = 8 mice per group). Semiquantification of histological changes showed that the pathological changes in SCD transgenic mice were significantly improved by PEG-ADA treatment (P < 0.05) as compared with untreated mice (Fig. 2b-d) . Consistent with these histological improvements, PEG-ADA treatment of SCD transgenic mice significantly decreased the elevated heme content in all tissues examined including lung, liver and spleen (P < 0.05; Fig. 2e ). Because SCD transgenic mice show marked pathological changes in their kidneys 13 and because approximately 25% of people with SCD develop renal dysfunction with proteinuria 18 , we investigated the potential therapeutic effect of chronic PEG-ADA treatment on renal damage and dysfunction. The increased microinfarction and cysts seen in the renal cortex and the vascular congestion in the renal medulla of SCD transgenic mice were reduced by chronic PEG-ADA treatment (Fig. 2f) . However, chronic PEG-ADA enzyme therapy had no significant effect in control mice (Fig. 2f) . Semiquantification of histological changes indicated that PEG-ADA treatment significantly (P < 0.05) reduced renal damage in SCD transgenic mice (Fig. 2g,h ). Consistent with the improved histological appearance of kidneys after PEG-ADA therapy, chronic PEG-ADA treatment of SCD transgenic mice also decreased proteinuria and increased urine osmolality, both of which indicate improvements in kidney function (Fig. 2i,j) . These studies provide additional evidence for the detrimental role of excess adenosine in the pathophysiology of SCD and for the beneficial effects of chronic PEG-ADA enzyme therapy. The concentration of ATP inside RBCs is extremely high (~5 mM). One factor contributing to elevation of plasma adenosine is probably hemolysis-mediated ATP release and subsequent conversion to adenosine. In support of this hypothesis, we found that ATP concentrations in the plasma of SCD transgenic mice were significantly elevated relative to those seen in plasma of wild-type mice (P < 0.05; Supplementary Fig. 2a ). Plasma ADA activity was very low in SCD transgenic mice and not different from that in wild-type mice ( Supplementary Fig. 2b) , consistent with the extremely low level of ADA activity in erythrocytes 17, 19, 20 .
Role of elevated adenosine in mice with acute sickle crisis It is accepted that hypoxia followed by reoxygenation triggers an acute sickle crisis in SCD 21 . As expected, we found that elevated steady-state plasma adenosine concentrations in SCD transgenic mice under normoxic conditions were further increased by exposing the mice to hypoxia for 2 h followed by reoxygenation for 4 h (Fig. 3a) . Treatment with PEG-ADA before hypoxia-reoxygenation resulted in significantly lowered adenosine concentrations (Fig. 3a) , reduced sickling (P < 0.05; Fig. 3b ) and attenuated hemolysis, as evidenced by decreased plasma hemoglobin concentration (Fig. 3c ) and plasma total bilirubin concentration (Fig. 3d) . Pretreatment with PEG-ADA also significantly (P < 0.05) prevented the hypoxia-reoxygenation-induced additional decrease in RBC numbers, hemoglobin concentration and hematocrit and also attenuated the hypoxia-reoxygenation-induced additional increase in RDW and in WBC numbers (Supplementary Table 1 ). These findings provide strong evidence that elevated adenosine levels are responsible for increased erythrocyte sickling and hemolysis after an acute sickle crisis event triggered by hypoxia-reoxygenation.
In addition to sickling and hemolysis, vaso-occlusion is a key endpoint of an acute crisis event 11 . We next assessed the effect of PEG-ADA therapy on hypoxia-reoxygenation-induced lung inflammation, a well-accepted measure of vaso-occlusion 11, 21 . Immunostaining with neutrophil-specific antibodies showed that hypoxia-reoxygenation increased neutrophil infiltration in the lungs of SCD transgenic mice compared to normoxic conditions (Fig. 3e) . PEG-ADA treatment reduced neutrophil infiltration in the lungs after hypoxia-reoxygenation (Fig. 3e) . Image quantification analysis confirmed that PEG-ADA treatment significantly (P < 0.05) lowered hypoxia-reoxygenationinduced neutrophil infiltration (Fig. 3f) . PEG-ADA treatment also significantly (P < 0.05) decreased the abundance of proinflammatory cytokines in the lungs of SCD transgenic mice, including interferon (IFN)-γ, interleukin (IL)-6, IL-1β and granulocyte-macrophage colonystimulating factor (GM-CSF; Fig. 3g ). These findings indicate that elevated adenosine levels not only underlie sickling induced by hypoxia-reoxygenation but also contribute to lung inflammation induced by hypoxia-reoxygenation, a major outcome of vasoocclusion in acute sickle crisis.
2,3-DPG underlies adenosine-mediated mouse RBC sickling
To identify factors responsible for adenosine-induced erythrocyte sickling, we re-examined the metabolic profiles of control and SCD transgenic mice, with a particular focus on erythrocyte-specific metabolites. We found that 2,3-diphosphoglycerate (2,3-DPG), an erythrocyte-specific by-product of glycolysis, was increased in whole blood from SCD transgenic mice (Supplementary Fig. 1 ). We confirmed that 2,3-DPG concentrations were significantly elevated in RBCs from SCD transgenic mice at steady state under normoxic conditions compared to wild-type control mice (Fig. 4a) . 2,3-DPG is an erythrocyte-specific metabolite that decreases the oxygen-binding affinity of hemoglobin [22] [23] [24] [25] and 2,3-DPG concentrations are increased in the RBCs of individuals with SCD and contribute to erythrocyte sickling under hypoxic conditions [26] [27] [28] . Because we found that adenosine levels were elevated at steady state (Fig. 1b) and responsible for sickling, it seemed possible that elevated 2,3-DPG concentration in SCD transgenic mice is a mediator of adenosine-induced sickling.
In support of this idea, we found that lowering steady-state adenosine concentrations in SCD transgenic mice by chronic PEG-ADA treatment resulted in a decrease in 2,3-DPG concentrations in RBCs (Fig. 4a) , increased hemoglobin oxygen-binding affinity measured by an increased percentage of saturated hemoglobin (Fig. 4b) and attenuated chronic sickling (Fig. 1c and Table 1) . Similarly, 2,3-DPG levels were further elevated by hypoxia-reoxygenation and pretreatment with PEG-ADA inhibited this elevation (Supplementary Fig. 3 ), indicating that elevated adenosine levels were responsible for the induction of 2,3-DPG by hypoxia-reoxygenation. PEG-ADA treatment also prevented the induction by hypoxia-reoxygenation of an acute vascular crisis with increased sickling, hemolysis and pulmonary inflammation (Fig. 3b-g ). These results indicate that adenosine is responsible for increased 2,3-DPG concentrations in erythrocytes from SCD transgenic mice and suggest that elevated 2,3-DPG concentrations contribute to both chronic sickling and acute sickle crisis in these mice.
Adenosine induces 2,3-DPG in mouse RBCs via PKA signaling
We next treated normal, mature primary mouse erythrocytes with 5′-N-ethylcarboxamidoadenosine (NECA), a potent, nonmetabolizable adenosine analog. NECA stimulated an increase in 2,3-DPG concentrations (Fig. 4c) , indicating that adenosine can directly induce 2,3-DPG in mature mouse RBCs.
Adenosine is a potent signaling molecule that elicits many physiological and pathological effects by activating G protein-coupled receptors on target cells 29 . Four such receptors have been identified-A 1 R, A 2A R, A 2B R and A 3 R-and each has a distinct affinity for adenosine and a distinct cellular and tissue distribution 29 . NECA-mediated induction of 2,3-DPG in normal mouse RBCs was prevented by theophylline (Fig. 4c) , a broad-spectrum adenosine receptor antagonist, indicating that induction of 2,3-DPG in erythrocytes by adenosine is mediated through adenosine receptors. To determine which adenosine receptor was responsible, we used RBCs from mice deficient in each of the four different adenosine receptors. RBCs isolated from mice genetically deficient in A 1 R, A 2A R or A 3 R (encoded by Adora1, Adora2a and Adora3, respectively) or from WT mice showed similar increases in 2,3-DPG concentration after treatment with NECA. By contrast, NECA did not induce 2,3-DPG in RBCs from mice genetically deficient in A 2B R (encoded by Adora2b) (Fig. 4d) . Immunostaining with A 2B R-specific antibodies 
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Hypoxiareoxygenation effect of hypoxia-reoxygenation with and without PEG-ADA treatment on proinflammatory cytokine abundance (IFN-γ, IL-6, IL-1β and GM-CSF) in lung homogenates from SCD transgenic mice. Mean ± s.e.m. from 5-7 mice per group; *P < 0.05 relative to SCD transgenic mice under normoxic conditions and **P < 0.05 relative to untreated SCD transgenic mice under hypoxia-reoxygenation conditions. confirmed that A 2B R was expressed in isolated wild-type mouse erythrocytes but not in those from A 2B R-deficient mice (Fig. 4e) . Finally, hypoxia-mediated induction of 2,3-DPG was significantly decreased in RBCs from A 2B R-deficient mice (Fig. 4f) . These results provide strong genetic evidence that A 2B R signaling is required for hypoxia-mediated induction of 2,3-DPG in normal mouse RBCs.
A 2B R is commonly coupled to adenylyl cyclase by the stimulatory G-protein subunit (G αs ) and increases intracellular cAMP, which activates PKA 30, 31 . We examined the role of cAMP-dependent activation of PKA in A 2B R-mediated induction of 2,3-DPG and found that NECA induced cAMP production in RBCs from wild-type mice but not in those from A 2B R-deficient mice (Fig. 4g) . Moreover, treatment of normal mouse RBCs with H-89, a specific, potent PKA inhibitor, significantly inhibited NECA-mediated induction of 2,3-DPG (P < 0.05; Fig. 4h ). These findings suggest that A 2B R-mediated cAMP-dependent activation of PKA is responsible for adenosinemediated induction of 2,3-DPG in normal mouse RBCs.
In vivo effects of A 2B R antagonism in SCD transgenic mice To determine the in vivo effect of A 2B R-mediated induction of 2,3-DPG on sickling in SCD transgenic mice, we treated these mice for 8 weeks with the A 2B R-specific antagonist PSB1115. Like PEG-ADA treatment (Fig. 4a) , PSB1115 treatment reduced both 2,3-DPG concentrations in RBCs (Fig. 4i) and the percentage of cells that were sickled (Table 1) . Moreover, chronic treatment with PSB1115 increased the half-life of RBCs in SCD transgenic mice from 2 d to 5.5 d (Fig. 4j) , a slightly greater improvement than that seen in mice treated with PEG-ADA (Fig. 1g) . In addition, complete blood count analysis showed significant improvement with PSB1115 treatment (P < 0.05), including increased total RBC numbers and hemoglobin concentration as well as decreased total WBC numbers, percentage of reticulocytes and RDW (Table 1) . Much like chronic PEG-ADA enzyme therapy, chronic treatment with PSB1115 reduced vascular congestion, vascular damage and necrosis in multiple tissues (Supplementary Fig. 4) . Overall, these studies provide in vivo evidence that A 2B R-mediated induction of 2,3-DPG is involved in erythrocyte sickling and subsequent multiple organ damage in SCD transgenic mice.
A 2B R-mediated 2,3-DPG induction in human RBC sickling To determine the pathophysiological significance of adenosine signaling in humans with SCD, we used HPLC to measure adenosine and 2,3-DPG in the blood of both healthy individuals and those with SCD (Supplementary Table 2) . Adenosine concentrations were significantly (P < 0.05) higher in the blood of individuals with SCD than in the blood of control subjects (Fig. 5a) . Consistent with earlier studies 26, 28 and with our in vivo findings in SCD transgenic mice (Fig. 4a) , we found that the concentration of 2,3-DPG was significantly higher in RBCs from individuals with SCD than in RBCs from control individuals (Fig. 5b) . Much as we had found in mice, we found that the A 2B R is expressed on human erythrocytes ( Supplementary  Fig. 5a ) and that NECA stimulated 2,3-DPG in a dose-and timedependent manner in primary cultured human RBCs from healthy individuals (Supplementary Fig. 5b-c) . NECA-stimulated induction of 2,3-DPG was inhibited by theophylline, indicating that adenosine receptor signaling is required (Supplementary Fig. 5d ). Supporting our genetic studies in mice, we found that NECA-mediated induction of 2,3-DPG in RBCs from healthy individuals was inhibited by an A 2B R antagonist (MRS1754) but not by other adenosine receptor antagonists tested (PSB36, SCH442416 and MRS3777, antagonists of A 1 R, A 2A R and A 3 R, respectively; Supplementary Fig. 5d ). In agreement with these findings, we found that the A 2B R agonist BAY 60-6583, but not the A 2A R agonist CGS21680, induced 2,3-DPG production in a Fig. 5e,f) . Thus, as in mice, the A 2B R is required for adenosine-mediated induction of 2,3-DPG in normal human RBCs.
To test the pathophysiological significance of the induction of 2,3-DPG by adenosine for erythrocyte sickling in humans, we incubated primary erythrocytes purified from individuals with SCD under hypoxic conditions (2% oxygen) to induce sickling in the presence or absence of PEG-ADA, NECA, MRS1754, H-89 or glycolate (an agent which depletes 2,3-DPG [26] [27] [28] ). Hypoxic conditions resulted in an induction of 2,3-DPG which was attenuated by PEG-ADA, MRS1754, H-89 or glycolate treatment to a similar degree (Fig. 5c) , indicating that adenosine induces 2,3-DPG through A 2B R signaling. By contrast, NECA stimulated a further increase in 2,3-DPG under hypoxic conditions (Fig. 5c) . These findings show that A 2B R-mediated activation of PKA is required for hypoxia to induce 2,3-DPG in human sickle erythrocytes.
Finally, to determine the functional role of A 2B R-mediated induction of 2,3-DPG in sickling, we tested the effect of oxygen pressure on the sickling of RBCs from individuals with SCD in the presence or absence of NECA, PEG-ADA, MRS1754, H-89 or glycolate. We found that the percentage of sickled cells was inversely dependent on oxygen concentration (Fig. 5d) . Treatment with PEG-ADA, MRS1754, H-89 or glycolate significantly reduced the percentage of sickled cells, whereas NECA treatment significantly enhanced the percentage of sickled cells under hypoxic conditions (Fig. 5d) . Overall, these findings show that the induction of 2,3-DPG by adenosine-mediated A 2B R activation followed by downstream signaling through PKA is a major underlying mechanism in hypoxia-mediated erythrocyte sickling in RBCs from individuals with SCD.
DISCUSSION
Using a high-throughput metabolomic screen, we found that adenosine and 2,3-DPG levels are elevated in the blood of SCD transgenic mice at steady state. These findings led us to discover that elevated adenosine signaling through A 2B R promotes sickling by inducing 2,3-DPG production. In addition, we showed that cAMP-dependent PKA activation functions downstream of A 2B R signaling and underlies the adenosine-induced increase in 2,3-DPG concentrations in erythrocytes. Lowering adenosine concentrations or interfering with activation of A 2B R reduced sickling, hemolysis and tissue injury in SCD transgenic mice both at steady state and during an acute crisis event. Finally, both adenosine and 2,3-DPG concentrations were elevated in the blood of individuals with SCD, and we showed that adenosine signaling through the A 2B R increases 2,3-DPG concentrations and induces sickling of RBCs derived from humans with SCD. Hence, our findings provide evidence for the pathogenic consequences of excessive adenosine signaling in SCD and suggest that interfering with adenosine signaling (particularly with A 2B R activation on erythrocytes) may be an effective mechanism-based therapy for preventing sickling and hemolysis in individuals with SCD and ultimately for reducing the life-threatening complications associated with SCD (Fig. 5e) .
It is well known that the concentration of adenosine, a metabolic signaling molecule, increases under energy depletion and ischemic or hypoxic conditions 14, 32, 33 . It has been speculated that increased adenosine levels under hypoxic conditions may be beneficial by increasing blood flow to ischemic or hypoxic tissue owing to its potent vasodilatory effect. However, our findings indicate that increased adenosine levels are detrimental in SCD because adenosine promotes sickling through the induction of 2,3-DPG in erythrocytes. Production of 2,3-DPG occurs only in RBCs and decreases the oxygen binding affinity of hemoglobin [22] [23] [24] [25] . Previous studies showed that erythrocyte 2,3-DPG is elevated in individuals with SCD and is involved in erythrocyte sickling under hypoxic conditions 26, 28 . To our knowledge, our findings provide the first evidence that elevated adenosine levels contribute to the induction of 2,3-DPG in RBCs, which leads to chronic sickling by decreasing the oxygen binding affinity of HbS. Acute hypoxia-reoxygenation treatment of SCD transgenic mice resulted in a further increase in the concentration of circulating adenosine and in erythrocyte 2,3-DPG concentrations, as well as in increased sickling and lung inflammation, presumed to result from acute vaso-occlusive events. Thus, although increased adenosine production is generally viewed as a beneficial response to hypoxia, it has detrimental effects in the setting of SCD. Our findings from both mouse and human studies support a model in which, under normal physiological conditions, adenosine regulates 2,3-DPG production to control the oxygen binding affinity of hemoglobin. However, in individuals with SCD, this normally beneficial effect becomes detrimental by decreasing the oxygen binding affinity of HbS, increasing polymerization of deoxyHbS and subsequently inducing RBC sickling (Fig. 5e) . Although SCD is the first genetic disorder for which a causative mutation was identified at the molecular level and is the most prevalent autosomal recessive disorder worldwide [34] [35] [36] , we remain unable to effectively control the polymerization of HbS and erythrocyte sickling, events that are central to the pathogenesis and pathophysiology of the disease 37 . Previously, we found that that increased adenosine levels in the penile tissues of SCD transgenic mice lead to increased corporal cavernosal relaxation in vitro and probably contribute to priapism, a dangerous and painful erectile disorder that is prevalent among men with SCD 38 . Our current findings highlight the possibility of preventing and treating this dangerous, painful and life-threatening hemolytic disease by interfering with an adenosine-induced sickling pathway. PEG-ADA has been used effectively for more than two decades to lower elevated adenosine concentrations in ADA-deficient individuals and mice 15, 17 and in this way prevent unwanted pathological effects caused by elevated adenosine. We show here that PEG-ADA can be used to reduce the deleterious effects of elevated adenosine in SCD transgenic mice. In contrast to these harmful effects of elevated adenosine concentrations, recent studies have shown that inhibition of invariant natural killer T cells (iNKT cells) through activation of A 2A R decreases pulmonary dysfunction in the NY1DD mouse model of SCD 39 . In view of the potentially protective effects of adenosinemediated A 2A R activation on iNKT cells, an A 2B R antagonist may be a better therapeutic choice than PEG-ADA, because specific antagonism of A 2B R will not prevent the potentially beneficial effects of adenosine in activating other types of adenosine receptors on cell types other than RBCs. By preventing erythrocyte sickling, interference with A 2B R signaling has the potential to reduce the morbidity and mortality associated with SCD.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
